Aqueous ophthalmic solutions of phentolamine and medical uses thereof
AssigneeOpus Genetics, Inc.
InventorAlan Meyer
Life of this patent
Estimating the term…
Abstract
The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
Claims30
A method of pupil reduction comprising administering to a subject an effective amount of an aqueous ophthalmic solution, wherein said method comprises:
- (a) storing said aqueous ophthalmic solution at temperature in the range of 2-8° C.;
- and
- (b) administrating said aqueous ophthalmic solution to the eye of a patient in the form of an eye drop;
- wherein said aqueous ophthalmic solution comprises:
- a. about 0.1% (w/v) to about 4% (w/v) of phentolamine or a pharmaceutically acceptable salt thereof;
- b. at least one polyol compound selected from the group consisting of mannitol, glycerol, propylene glycol, ethylene glycol, sorbitol, and xylitol;
- c. about 0.1 mM to about 10 mM of at least one buffer;
- and
- d. water;
- provided the aqueous ophthalmic solution does not contain any additional ingredient that is a chelating agent, and wherein the aqueous ophthalmic solution does not contain any additional ingredient that is a stabilizer;
- and
- wherein said aqueous ophthalmic solution has a pH of about 4.0 to about 7.5.
A method of pupil reduction comprising administering to a subject an effective amount of an aqueous ophthalmic solution, wherein said method comprises:
- (a) storing said aqueous ophthalmic solution at temperature in the range of 2-8° C.;
- and
- (b) administrating said aqueous ophthalmic solution to the eye of a patient in the form of an eye drop;
- wherein the aqueous ophthalmic solution consists of:
- a. about 0.1% (w/v) to about 4% (w/v) of phentolamine or a pharmaceutically acceptable salt thereof;
- b. at least one polyol compound selected from the group consisting of mannitol, glycerol, propylene glycol, ethylene glycol, sorbitol, and xylitol;
- c. about 0.1 mM to about 10 mM of at least one buffer;
- d. water;
- and
- e. optionally one or more of a poly(C2-4 alkylene)glycol polymer, dextran, pharmaceutically acceptable carrier, cellulose agent, carbohydrate, alkali metal halide, alkaline earth metal halide, boric acid, cyclodextrin, dextrose, glycerin, urea, viscosity modifying agent, solubilizing agent, surfactant, demulcent polymer, wetting agent, or water-miscible solvent.
Dependencies are inferred from the claim text.